Abstract: Disclosed herein is a method for separating an arsenic mineral from a copper-bearing material, including the steps of grinding a copper-bearing material containing arsenic, adding water to the copper-bearing material to prepare a slurry, and adding a flotation agent including a depressant, a frother, and a collector to the slurry and blowing air into the slurry for performing flotation to obtain a copper concentrate, wherein the depressant is a chelator. As the chelator, a polyethyleneamine or the like is used. Particularly, when triethylenetetramine is used as the chelator, the amount of triethylenetetramine to be added is preferably 1 to 10 equivalents relative to the amount of soluble copper generated by oxidation of the copper-bearing material, and the pH of the slurry is more preferably adjusted to 7 or more but 8 or less before the slurry is subjected to the flotation.

Abstract: Sorbents for removal of mercury and other pollutants from gas streams, such as a flue gas stream from coal-fired utility plants, and methods for their manufacture and use are disclosed. Embodiments include brominated sorbent substrate particles having a carbon content of less than about 10%. Other embodiments include one or more oxidatively active halides of a nonoxidative metal dispersed on sorbent substrate particles mixed with activated carbon in an amount up to 30% by weight. Further embodiments include physical blending of a flow modifier into the sorbent composition.

Abstract: The present invention pertains to catalyst systems for nitrogen oxide, carbon monoxide, hydrocarbon, and sulfur reactions that are free or substantially free of platinum group metals. The catalyst system of the present invention comprise a substrate and a washcoat, wherein the washcoat comprises at least one oxide solid, wherein the oxide solid comprises one or more selected from the group consisting of a carrier material oxide, a catalyst, and mixtures thereof. The catalyst system may optionally have an overcoat, wherein the overcoat comprises at least one oxide solid, wherein the oxide solid comprises one or more selected from the group consisting of a carrier material oxide, a catalyst, and mixtures thereof. The catalyst comprises one or more selected from the group consisting of a ZPGM transition metal catalyst, a mixed metal oxide catalyst, a zeolite catalysts, or mixtures thereof.

Abstract: Provided are improved exhaust gas cleaning systems and methods for treating exhaust gas from a combustion source that include a hydrogen generation system, a regenerable sulfur oxides trap, and a regenerable nitrogen storage reduction (NSR) catalyst trap. The improved exhaust gas cleaning systems and methods allow for the sulfur released from the sulfur trap to pass through the nitrogen oxide trap with no or little poisoning of NOx storage and reduction sites, which significantly improves NSR catalyst trap lifetime and performance to meet future emissions standards. The disclosed exhaust gas cleaning systems are suitable for use in internal combustion engines (e.g., diesel, gasoline, CNG) which operate with lean air/fuel ratios over most of the operating period.

Abstract: The present invention concerns the selective removal of nitrogen oxides (NOx) from gases. In particular, the invention concerns a process, a highly alkali metal resistant heteropoly acid promoted catalyst and the use of said catalyst for removal of NOx from exhaust or flue gases, said gases comprising alkali or earth alkali metals. Such gases comprise for example flue gases arising from the burning of biomass, combined biomass and fossil fuel, and from waste incineration units. The process comprises the selective catalytic reduction (SCR) of NOx, such as nitrogen dioxide (NO2) and nitrogen oxide (NO) with ammonia (NH3) or a nitrogen containing compound selected from ammonium salts, urea or a urea derivative or a solution thereof as reductant.

Abstract: A method of forming methanol, formaldehyde, formic acid and ammonium pentaborate tetrahydrate includes the steps of providing ammonium hydroxide and producing air bubbles within the ammonium hydroxide to form a solution. Sodium borohydride is added and dissolved within the solution of air bubbled ammonium hydroxide to form methanol, formaldehyde, formic acid and ammonium pentaborate tetrahydrate. An alternative method of forming methanol, formaldehyde, formic acid and ammonium pentaborate tetrahydrate is also provided which includes the steps of providing ammonium hydroxide and dissolving sodium borohydride therein to form a solution. Sodium bicarbonate is added to the solution of ammonium hydroxide and sodium borohydride to form methanol, formaldehyde, formic acid and ammonium pentaborate tetrahydrate.

Abstract: Provided herein are methods of synthesizing large-pore periodic mesoporous quartz. Using the methods herein, large-pore periodic mesoporous quartz has been synthesized at a lower pressure and a temperature than in any previous mesoporous crystalline method, yielding a unique mesoporous article having crystalline pore walls. For example, the methods involve modified nanocasting methods using a mesoporous starting material comprising silica, carbon as a an infiltrating pore filler, followed by application of pressure and heat sufficient to crystallize silica in the infiltrated starting material to form a mesoporous crystalline article having crystalline pore walls therein, and useful in many applications, including as a catalyst.

Abstract: The invention relates to a firing support for ceramics formed from a carbon substrate at least partially covered by a coating based on silicon carbide (SiC), said coating additionally adhering to said substrate. The invention also relates to a process for obtaining such a support.

Abstract: In various implementations, feed streams that include ultrapure, high-pressure hydrogen streams and ultrapure, high-pressure nitrogen streams are reacted to produce ultrapure, high-pressure feed gas in a stoichiometric ratio to an ammonia synthesis reactor loop without or independent of including a methanol loop purge gas.

Abstract: An atomic carbon material and a preparation method thereof having ion adsorption ability superior to fullerenes and nano-tubes are provided. This atomic carbon material is in a state existing as an organic compound and in a state close to an atom with a diameter of 1 nm or less (theoretically about 1.66 angstrom), and is a bulk where they are congregated with each other with an interatomic force or a particle with a particle size of 1 nm or less. This atomic carbon material is manufactured by heating a raw material composed of an organic material which does not include carbon units in an inactive atmosphere at a predetermined temperature while sequentially increasing the temperature and by individually separating expected elements except for carbon in the aforementioned atmosphere and the organic material from being bonded with carbon by thermally decomposing in order from an element having a lower decomposition temperature at a temperature of 450 C or lower.

Abstract: This invention is to provide a method for the production of diamond at a high rate and in a high efficiency using in-liquid plasma. The present invention is a method for the production of diamond using electromagnetic waves irradiated to a liquid containing carbon, hydrogen and oxygen in which the ratio of hydrogen atoms to the sum of carbon atoms and hydrogen atoms is from 0.75 to 0.82 and the ratio of carbon atoms to the sum of carbon atoms and oxygen atoms is from 0.47 to 0.58 so as to generate plasma in the liquid.

Abstract: Disclosed therein is a method for preparing a polyacrylonitrile-based polymer for preparation of carbon fiber having a melting point controlled by selecting an optimal energy of microwave, and a method for preparing a carbon fiber through melt spinning using the preparation method for polyacrylonitrile-based polymer. The present invention uses microwave to control the properties of the polyacrylonitrile-based polymer in a simplified way and prepare the polymer optimized for preparation of carbon fiber precursor through melt spinning for a short polymerization time, and provides a means for mass production of the polyacrylonitrile-based polymer being suitable for melt spinning at a temperature lower than the stabilization temperature and acquiring properties adequate to preparation of carbon fiber through stabilization. Hence, the present invention is expected to contribute to mass production of high-performance carbon fibers at reduced cost.

Abstract: The invention relates to an anode for lithium secondary battery comprising vapor grown carbon fiber uniformly dispersed without forming an agglomerate of 10 ?m or larger in an anode active material using natural graphite or artificial graphite, which anode is excellent in long cycle life and large current characteristics. Composition used for production for the anode can be produced, for example, by mixing a thickening agent solution containing an anode active material, a thickening agent aqueous solution and styrene butadiene rubber as binder with a composition containing carbon fiber dispersed in a thickening agent with a predetermined viscosity or by mixing an anode active material with vapor grown carbon fiber in dry state and then adding polyvinylidene difluoride thereto.

Abstract: A honeycomb carrier for an exhaust gas-cleaning catalyst to clean e.g. an exhaust gas of an automobile particularly containing NOx, wherein the material for the honeycomb carrier is an aluminum magnesium titanate sintered product obtained by firing at from 1,000 to 1,700° C. a molded product formed from a raw material mixture comprising 100 parts by mass, as calculated as oxides, of a mixture comprising a Mg-containing compound, an Al-containing compound and a Ti-containing compound in the same metal component ratio as the metal component ratio of Mg, Al and Ti in an aluminum magnesium titanate represented by the empirical formula MgxAl2(1+x)Ti(1+x)O5 (wherein 0?x?1), and from 1 to 10 parts by mass of an alkali feldspar represented by the empirical formula (NayK1?y)AlSi3O8 (wherein 0?y?1).

Abstract: Liquid compositions of ammonia borane and a suitably chosen amine borane material were prepared and subjected to conditions suitable for their thermal decomposition in a closed system that resulted in hydrogen and a liquid reaction product.

Abstract: Provided is a process and device for exchanging heat energy between three or more streams in a microchannel heat exchanger which can be integrated with a microchannel reactor to form an integrated microchannel processing unit. The combining of a plurality of integrated microchannel devices to provide the benefits of large-scale operation is enabled. In particular, the microchannel heat exchanger enables flexible heat transfer between multiple streams and total heat transfer rates of about 1 Watt or more per core unit volume expressed as W/cc.

Abstract: Hierarchical porosity material consisting of at least two elementary spherical particles having a maximum diameter of 200 microns, at least one of said spherical particles comprises at least one matrix based on silicon oxide and exhibiting crystallized walls, said material having a macropore volume measured by mercury porosimetry ranging between 0.05 and 1 ml/g, a mesopore volume measured by nitrogen volumetric analysis ranging between 0.01 and 1 ml/g and a micropore volume measured by nitrogen volumetric analysis ranging between 0.03 and 0.4 ml/g. The preparation of said material and use of same as adsorbent or as acidic solid is also described.

Abstract: Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.

Abstract: A new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications, including, a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response is provided. Complexes including a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells is also provided. The cellular delivery molecules may include one or more polymers, e.g., polyamides, dendritic macromolecules and carbohydrate-containing degradable polyesters.

Abstract: One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the radionuclide complexes are also described. Another aspect of the invention relates to imidazolyl and pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.

Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.

Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumors following cancer treatment.

Abstract: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide or aptamer that specifically binds to the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that specifically bind to neurons or nerves and for compositions thereof.

Abstract: A mucosal or cutaneous medicinal or hygiene system, comprising (a) a gas-driven foam dispenser; and (b) a fluid composition comprising (i) as the only foaming agent one or more polysaccharides, gelatins, synthetic polymers selected from the group consisting of ethylene oxide homo- and copolymers having a weight average molecular weight of at least 10,000, and homo and copolymers comprising in polymerized form acrylic acid, an acrylic acid salt, acrylamide, vinylalcohol, vinylacetate, vinylpyrrolidone or vinylpyridine, or a combination thereof; (ii) a liquid diluent, and (iii) an active ingredient for mucosal or cutaneous medicinal treatment or hygiene.

Abstract: EDTA and EDTA related compositions and methods of using them are described herein. The compositions can have improved bioavailability over EDTA alone. The compositions can be useful in the treatment or prevention of atherosclerosis or for the treatment of heavy metal accumulation.

Abstract: The present invention relates to a cosmetic composition for caring for and/or making up keratin fibers, in stick form, which can be applied dry, (i), in the form of an emulsion comprising a fatty phase dispersed in an aqueous phase, the said fatty phase comprising carnauba wax and/or synthetic beeswax, in a content of at least 2% by weight relative to the total weight of the said composition, and (ii) having a shear hardness of between 375 g/m and 5000 g/m, the said shear hardness being measured at 20° C. on a cylindrical stick using a rigid tungsten wire 250 ?m in diameter, by advancing the wire relative to the stick at a rate of 100 mm/minute. The invention also relates to the process for coating keratin fibers comprising at least one step of applying a composition in accordance with the invention.

Abstract: The invention relates to emulsifiers comprising glycerin-modified organopolysiloxanes and to their use for the preparation of extraordinarily stable emulsions and dispersions.

Abstract: Agent for treating fibers containing keratin, particularly human hair, having in a cosmetically acceptable carrier, (a) at least one amphiphilic, cationic polymer comprising at least one structural unit of formulae (I) to (IV), wherein R1 and R4 independently=H or methyl; X1 and X2 independently=O or NH, A1 and A2 independently=ethan-1,2-diyl, propan-1,3-diyl or butan-1,4-diyl, R2, R3, R5 and R6 independently=(C1-C4) alkyl, R7?(C8-C30) alkyl, and (b) at least one film-forming anionic and/or stabilizing anionic polymer comprising at least one structural unit of formula (V) and at least one structural unit of formula (VI), wherein R8 and R9 independently=hydrogen or methyl, with the proviso that R8 and R9 are not simultaneously methyl, R10=hydrogen or methyl, R11=carbamoyl, linear or branched (C4 to C12) alkylaminocarbonyl, linear or branched (C4 to C12) alkylaminoethyl-aminocarbonyl, linear or branched (C4 to C12) alkylaminopropyl-aminocarbonyl, linear or branched (C4 to C12) alkyloxycarbonyl, linear or branch

Abstract: The present invention relates to the use of a composition comprising 2-bromo-2-nitropropane-1,3-diol for tissue preservation and more particularly for the preservation of bodies and anatomical parts or for carrying out embalming procedures.

Abstract: The present invention relates to a high concentration functional material gel composition and effective delivery composition thereof. More specifically, the present invention relates to a high concentration functional material gel composition comprising a small organic molecule having at least one of a carbonyl group and at least one of an isolated hydroxyl group from the carbonyl group as a defined mandatory element holding and delivering amounts of functional materials. This is achieved without depending on employing additional incompatible materials in the functional composition, including for example inorganic salts, polymers, absorbents petroleum waxes, and paraffin hydrocarbons.

Abstract: A deodorant comprises triethyl citrate, zinc glycinate, and water. The deodorant has a pH of 5.5 to 6.5.

Abstract: The invention provides skin protecting and penetrating, easy-to-administer base and active agent-containing compositions, such as those including hydrocortisone, for treating the skin of mammals for different dermatologic disorders. This is effected by topically administering effective amounts of the compositions thereto in forms that address the skin and mucosa of the mouth and lips, and the rest of the body. Additionally, an optional flavoring addition to these products affords significantly better tasting, and less bitter, compositions, allowing a more pleasant experience and better compliance by patients. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in a form of a solid roll-on stick in a variety of sizes and of a jar or pot.

Abstract: The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly poly (hydroxyalkyl(meth) acrylamide mono/di-lactate_interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention comprise monomers, which have modifiable functionality. The functionality of the monomers can for example be modified by the presence of hydrolysable groups. The modification is effected by the incubation, leading to a change of the water solubility characteristics of the polymer. The polymers used in the present invention contain hydrolysable chemical groups. As a result the polymer's solution characteristics, specifically its lower critical solution temperature (LCST), change upon incubation.

Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Abstract: The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in an appropriate host cell, recovering the immunogenic complexes from the cell culture and the cells, and purifying the immunogenic complexes by affinity chromatography. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the genetic sequence. The complexes can be used as a vaccine to elicit specific immune responses against cancer or infected cells, and to treat or prevent cancer or infectious diseases.

Abstract: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.

Abstract: Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for >40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy.

Abstract: A recombinant vector comprises simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -38 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -383 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.

Abstract: The present invention relates to a method for the prevention, treatment and reduction of gastro-intestinal inflammation in a subject by administering a specific Bifidobacterium bacteria, in particular a fermented dairy product comprising said specific Bifidobacterium bacteria for the prevention, treatment and reduction of gastro-intestinal inflammation, in particular for the prevention and treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC) and/or Crohn's Disease (CD) and for the prevention and treatment of Irritable Bowel Syndrome (IBS).

Abstract: Bacterial agents for preparing compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents are extracts of a bacterium, or a bacterium and are selected for their adhesion to skin cells and anti-adhesion to pathogens of the cutaneous system. The invention also relates to compositions containing such agents.

Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.

Abstract: Dermatological and cosmetic compositions and methods are provided to reduce the appearance of biological and/or environmentally-caused aging.

Abstract: The invention relates to glutamine endopeptidase enzymes from Rothia spp. bacteria that are naturally associated with the oral cavity, formulations comprising the glutamine endopeptidase enzymes and the use thereof for the treatment, prevention of allergic reaction and diagnosis of gluten allergy related diseases such as Celiac Sprue, gluten allergy and/or dermatitis herpetiformis.

Abstract: The present invention features methods and kits that utilize Ang-2 antagonists for the treatment, inhibition, and prevention of a systemic anthrax infection. The invention described herein also features methods for the diagnosis of a systemic anthrax infection by detecting elevated levels of Ang-2 in the serum of a subject.

Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or tremelimumab in combination with other chemotherapeutic agents such as dasatinib, imatinib, paclitaxel, gemcitabine, cisplatin or etoposide.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Abstract: The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.

Abstract: Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.

Abstract: The present invention relates to anti-human PAX 5 antibodies capable of binding to one or more epitopes located within the C-terminal regulatory domain of PAX 5. In particular the invention relates to an antibody, antigen binding fragment or recombinant protein thereof, which is capable of specific binding to an epitope located within the C-terminal fragment of human PAX 5 protein, wherein said epitope comprises from 3 to 17 amino acid residues of amino acid sequence GSPYYYSAAARGAAPPA (SEQ ID NO:2). The invention also relates to immunogenic peptide sequences for the production of the antibodies, diagnostic and therapeutic applications comprising using the antibodies and formulations comprising thereof.